The efficacy and safety of cefepime or meropenem in the treatment of febrile neutropenia in patients with lung cancer. A randomized phase II study.

@article{Fujita2016TheEA,
  title={The efficacy and safety of cefepime or meropenem in the treatment of febrile neutropenia in patients with lung cancer. A randomized phase II study.},
  author={Masaki J. Fujita and Takemasa Matsumoto and Yuuichi Inoue and Hiroshi Wataya and Koichi Takayama and Masayuki Ishida and Noriyuki Ebi and Junji Kishimoto and Yukito Ichinose},
  journal={Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy},
  year={2016},
  volume={22 4},
  pages={235-9}
}
Febrile neutropenia frequently develops after chemotherapy. There is little evidence to indicate the type of antimicrobial agents that should be used in the treatment of febrile neutropenia in patients with solid tumors. The objective is to determine the efficacy and safety of cefepime (CFPM) and meropenem (MEPM) in the treatment of febrile neutropenia in lung cancer patients in a prospective randomized study. FN patients with lung cancer were randomly divided into CFPM or MEPM groups. The… CONTINUE READING

Similar Papers

Loading similar papers…